Are all monitoring boundaries equally ethical?

Controlled Clinical Trials

Volumn 24, Issue 5, 2003, Pages 585-588

  Ellenberg, Susan S ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORRELATION ANALYSIS; DATA ANALYSIS; HEALTH CARE POLICY; INFORMED CONSENT; MEDICAL ETHICS; MEDICAL RESEARCH; NOTE; OUTCOMES RESEARCH; PATIENT MONITORING; RISK ASSESSMENT; SEQUENTIAL ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TECHNIQUE; BIOMEDICAL AND BEHAVIORAL RESEARCH; CLINICAL TRIAL; DRUG APPROVAL; DRUG MONITORING; ETHICS; HUMAN; PERSONNEL; RESEARCH SUBJECT; UNITED STATES;

BIOMEDICAL AND BEHAVIORAL RESEARCH;

CLINICAL TRIALS; DRUG APPROVAL; DRUG MONITORING; HUMANS; RESEARCH PERSONNEL; RESEARCH SUBJECTS; UNITED STATES;

EID: 1542547080     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(03)00090-4     Document Type: Editorial

References (41)

1. Hill B.A. Medical ethics and controlled trials. BMJ. 1:1963;1043-1049.
2. Weinstein M.C. Allocation of subjects in medical experiments. N Engl J Med. 24:1974;1278-1285.
3. Gehan E.A. The evaluation of therapies: historical control studies. Stat Med. 3:1984;315-324.
4. Hellman S., Hellman D.S. Of mice but not of men. N Engl J Med. 324:1991;1585-1589.
5. Chalmers T.C. The need for early randomization in the development of new drugs for AIDS. J Acquir Immune Defic Syndr. 3:1990;S10-S15.
6. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 317:1987;141-145.
7. Palmer C.R., Rosenberger W.F. Ethics and practice: alternative designs for phase III randomized clinical trials. Control Clin Trials. 20:1999;172-186.
8. Rothman K., Michels K. The continuing unethical use of placebo controls. N Engl J Med. 331:1994;94-98.
9. Freedman B., Weijer C., Cranley Glass K. Placebo orthodoxy in clinical research I: empirical and methodological myths. J Law Med Ethics. 24:1996;243-251.
10. Freedman B., Cranley Glass K., Weijer C. Placebo orthodoxy in clinical research II: ethical legal and regulatory myths. J Law Med Ethics. 24:1996;252-259.
11. Temple R.T., Ellenberg S.S. Placebo-controlled trials and active-control trials in the evaluation of new treatments Part 1: ethical and scientific issues. Ann Intern Med. 133:2000;456-464.
12. Ellenberg S.S., Temple R.T. Placebo-controlled trials and active-control trials in the evaluation of new treatments Part 2: practical issues and specific cases. Ann Intern Med. 133:2000;464-470.
13. Beecher H.K. Ethics and clinical research. N Engl J Med. 27:1966;1354-1360.
14. Zelen M. A new design for randomized clinical trials. N Engl J Med. 300:1979;1242-1245.
15. Ellenberg S.S. Randomization designs in comparative clinical trials. N Engl J Med. 310:1984;1404-1408.
16. Levine R.J. Deferred consent. Control Clin Trials. 4:1991;525-545.
17. Ellenberg S.S. Informed consent: protection or obstacle? Some emerging issues. Control Clin Trials. 18:1997;628-636.
18. Shaw L.W., Chalmers T.C. Ethics in cooperative clinical trials. Ann N Y Acad Sci. 169:1970;487-495.
19. Meinert C.L. Clinical trials and treatment effect monitoring. Control Clin Trials. 19:1998;515-522.
20. Souhami R.L. The clinical importance of early stopping of randomized trials in cancer treatments. Stat Med. 13:1994;1293-1295.
21. Angell M. Investigators' responsibilities for human subjects in developing countries. N Engl J Med. 342:2000;967-969.
22. Lurie P., Wolfe S.M. Unethical trials of interventions to reduce perinatal transmission of human immunodeficiency virus in developing countries. N Engl J Med. 337:1997;853-856.
23. Dettweiler U., Simon P. Points to consider for ethics committees in human gene therapy trials. Bioethics. 15:2001;491-500.
24. Discussion. Ellenberg S.S., Geller N., Simon R., Yusuf S. Stat Med. Proceedings of Workshop on Practical Issues in Data Monitoring of Clinical Trials. 12:1993;521-525
25. Migrino R.Q., Topol E.J. A matter of life and death? The Heart Protection Study and protection of clinical trial participants. Control Clin Trials. 24:2003;501-505.
26. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 360:2002;7-22.
27. Heart Special Project Committee. Organization, review and administration of cooperative studies (Greenberg Report): a report from the Heart Special Project Committee to the National Advisory Council, May 1967. Control Clin Trials. 9:1988;137-148.
28. Ellenberg S.S., Geller N., Simon R., Yusuf S. Stat Med. Proceedings of Workshop on Practical Issues in Data Monitoring of Clinical Trials. 12:1993;415-616
29. Ellenberg S.S., Myers M.W., Blackwelder W.C., Hoth D.F. The use of external monitoring committees in clinical trials of the National Institute of Allergy and Infectious Diseases. Stat Med. 12:1993;461-467.
30. Green S.J., Fleming T.R., O'Fallon J.R. Policies for study monitoring and interim reporting of results. J Clin Oncol. 5:1987;1477-1484.
31. US Food and Drug Administration. Draft Guidance for Clinical Trial Sponsors on the Establishment and Operation of Clinical Trial Data Monitoring Committees. Rockville, Maryland: Food and Drug Administration, 2001. « http://www.fda/gov/cber/gdlns/clindatmon.htm ». Accessed June 9, 2003.
32. Ellenberg S.S., Fleming T.R., DeMets D.L. Data monitoring committees in clinical trials: a practical perspective. 2002;John Wiley, Chichester.
33. Armitage P., McPherson C.K., Rowe B.C. Repeated significance tests on accumulating data. J R Stat Soc. 132A:1969;235-244.
34. Souhami R.L., Whitehead J. Stat Med. Proceedings of Workshop on Early Stopping Rules in Cancer Clinical Trials. 13:1994;1289-1500
35. Lilford R.J., Braunholtz D., Edwards S., Stevens A. Monitoring clinical trials - interim data should be publicly available. BMJ. 323:2001;441-442.
36. Bird S.M. Dissemination of decisions on interim analyses needs wider debate. (letter) BMJ. 323:2001;1424.
37. Richards S.M. Interim data should not be publicly available. (letter) BMJ. 323:2001;1424.
38. Thornton H. Caution may be warranted in releasing interim trial data. (letter) BMJ. 323:2001;1424-1425.
39. Perry D. Several points are contentious. (letter) BMJ. 323:2001;1425.
40. Reidpath D. Interim data are at least as important as interim analyses. (letter) BMJ. 323:2001;1425.
41. Henk J.M. Latest data from START trial should be made available. (letter) BMJ. 323:2001;1425.